104 related articles for article (PubMed ID: 21036701)
1. E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking.
Ye Y; Tellez JD; Durazo M; Belcher M; Yearsley K; Barsky SH
Anticancer Res; 2010 Oct; 30(10):3903-10. PubMed ID: 21036701
[TBL] [Abstract][Full Text] [Related]
2. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma.
Tomlinson JS; Alpaugh ML; Barsky SH
Cancer Res; 2001 Jul; 61(13):5231-41. PubMed ID: 11431364
[TBL] [Abstract][Full Text] [Related]
3. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma.
Alpaugh ML; Tomlinson JS; Kasraeian S; Barsky SH
Oncogene; 2002 May; 21(22):3631-43. PubMed ID: 12032865
[TBL] [Abstract][Full Text] [Related]
4. The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin.
Ye Y; Tian H; Lange AR; Yearsley K; Robertson FM; Barsky SH
Oncogene; 2013 Mar; 32(13):1702-13. PubMed ID: 22580607
[TBL] [Abstract][Full Text] [Related]
5. Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma.
Alpaugh ML; Tomlinson JS; Ye Y; Barsky SH
Am J Pathol; 2002 Aug; 161(2):619-28. PubMed ID: 12163386
[TBL] [Abstract][Full Text] [Related]
6. Early to intermediate steps of tumor embolic formation involve specific proteolytic processing of E-cadherin regulated by Rab7.
Ye Y; Gao JX; Tian H; Yearsley K; Lange AR; Robertson FM; Barsky SH
Mol Cancer Res; 2012 Jun; 10(6):713-26. PubMed ID: 22638108
[TBL] [Abstract][Full Text] [Related]
7. Persistent E-cadherin expression in inflammatory breast cancer.
Kleer CG; van Golen KL; Braun T; Merajver SD
Mod Pathol; 2001 May; 14(5):458-64. PubMed ID: 11353057
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
10. Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression.
Mauro L; Catalano S; Bossi G; Pellegrino M; Barone I; Morales S; Giordano C; Bartella V; Casaburi I; Andò S
Cancer Res; 2007 Apr; 67(7):3412-21. PubMed ID: 17409452
[TBL] [Abstract][Full Text] [Related]
11. Geometric tumor embolic budding characterizes inflammatory breast cancer.
Modi AP; Nguyen JPT; Wang J; Ahn JS; Libling WA; Klein JM; Mazumder P; Barsky SH
Breast Cancer Res Treat; 2023 Feb; 197(3):461-478. PubMed ID: 36473978
[TBL] [Abstract][Full Text] [Related]
12. Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines.
Pierceall WE; Woodard AS; Morrow JS; Rimm D; Fearon ER
Oncogene; 1995 Oct; 11(7):1319-26. PubMed ID: 7478552
[TBL] [Abstract][Full Text] [Related]
13. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
14. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer.
Shirakawa K; Tsuda H; Heike Y; Kato K; Asada R; Inomata M; Sasaki H; Kasumi F; Yoshimoto M; Iwanaga T; Konishi F; Terada M; Wakasugi H
Cancer Res; 2001 Jan; 61(2):445-51. PubMed ID: 11212228
[TBL] [Abstract][Full Text] [Related]
15. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
16. Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas.
De Medina SG; Popov Z; Chopin DK; Southgate J; Tucker GC; Delouvée A; Thiery JP; Radvanyi F
Oncogene; 1999 Oct; 18(41):5722-6. PubMed ID: 10523852
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation regulates cadherin switching in squamous cell carcinoma.
Chen Q; Lipkina G; Song Q; Kramer RH
Biochem Biophys Res Commun; 2004 Mar; 315(4):850-6. PubMed ID: 14985090
[TBL] [Abstract][Full Text] [Related]
18. Curcumin alters the migratory phenotype of nasopharyngeal carcinoma cells through up-regulation of E-cadherin.
Wong TS; Chan WS; Li CH; Liu RW; Tang WW; Tsao SW; Tsang RK; Ho WK; Wei WI; Chan JY
Anticancer Res; 2010 Jul; 30(7):2851-6. PubMed ID: 20683022
[TBL] [Abstract][Full Text] [Related]
19. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma.
Kim CH; Kim J; Kahng H; Choi EC
Ann Surg Oncol; 2007 May; 14(5):1565-74. PubMed ID: 17294073
[TBL] [Abstract][Full Text] [Related]
20. A novel human xenograft model of inflammatory breast cancer.
Alpaugh ML; Tomlinson JS; Shao ZM; Barsky SH
Cancer Res; 1999 Oct; 59(20):5079-84. PubMed ID: 10537277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
